Structure-based design, parallel synthesis, structure - Activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives

Journal of Medicinal Chemistry

Volumn 48, Issue 11, 2005, Pages 3858-3873

  Ranise, Angelo ^a   Spallarossa, Andrea ^a   Cesarini, Sara ^a   Bondavalli, Francesco ^a   Schenone, Silvia ^a   Bruno, Olga ^a   Menozzi, Giulia ^a   Fossa, Paola ^a   Mosti, Luisa ^a   La Colla, Massimiliano ^b   Sanna, Giuseppina ^b   Murreddu, Marta ^b   Collu, Gabriella ^b   Busonera, Bernardetta ^b   Marongiu, Maria Elena ^b   Pani, Alessandra ^b   La Colla, Paolo ^b   Loddo, Roberta ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; BENZENE DERIVATIVE; DELAVIRDINE; EFAVIRENZ; LIGAND; MSC 127; NEVIRAPINE; NITRO DERIVATIVE; NSC 615985; PHTHALIMIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; S 2720; THIAZOLE DERIVATIVE; THIOCARBAMIC ACID DERIVATIVE; THIOUREA DERIVATIVE; TIVIRAPINE; TROVIRDINE; UC 38;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; VIROGENESIS; VIRUS MUTANT; VIRUS RESISTANCE;

ANTI-HIV AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MUTATION; PHENYLTHIAZOLYLTHIOUREA; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOCARBAMATES;

EID: 20144368570     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049252r     Document Type: Article

References (64)

1. Jonckheere, H.; Anne, J.; De Clercq, E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 2000, 20, 129-154.
2. De Clercq, E. New developments in anti-HIV chemotherapy. Farmaco 2001, 56, 3-12.
3. Artico, M. Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Farmaco 1996, 51, 305-331.
4. Tucker, T. J.; Lumma, W. C.; Culberson, J. C. Development of non nucleoside HIV reverse transcriptase inhibitors. Methods Enzymol. 1996, 275, 440-472.
5. De Clercq, E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
6. De Clercq, E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 1995, 8, 200-239.
7. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
8. De Clercq, E. New perspectives for the treatment of HIV infections. Collect. Czech. Chem. Commun. 1998, 63, 449-479.
9. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Expert Opin. Invest. Drugs 1994, 3, 253-271.
10. Pedersen, O. S.; Pedersen, E. B. Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antiviral Chem. Chemother. 1999, 10, 285-314.
11. Artico, M. Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): the DABO family. Drugs Future 2002, 27, 159-175.
12. Pedersen, O. S.; Pedersen, E. B. The flourishing syntheses of non-nucleoside reverse transcriptase inhibitors. Synthesis 2000, 4, 479-495.
13. For recent reviews, see the following: (a) De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future. Chem. Biodiversity 2004, 1, 44-64.
14. (b) Balzarini, J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency vitrus type 1. Curr. Top. Med. Chem. 2004, 4 (9), 921-944.
15. Tachedjian, G.; Goff, S. P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Invest. Drugs. 2003, 4 (8), 966-973.
16. Lindberg, J.; Sigurdsson, S.; Lowgren, S.; Andersson, H. O.; Sahlberg, C.; Noreen, R.; Fridborg, K.; Zhang, H.; Unge, T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 2002, 269, 1670-1677.
17. Ren, J.; Diprose, J.; Warren, J.; Esnouf, R. M.; Bird, L. E.; Ikemizu, S.; Slater, M.; Milton, J.; Balzarini, J.; Stuart, D. I.; Stammers, D. K. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J. Biol. Chem. 2000, 275, 5633-5639.
18. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000, 8, 1089-1094.
19. Ren, J.; Esnouf, R. M.; Hopkins, A. L.; Stuart, D. I.; Stammers, D. K. Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. J. Med. Chem. 1999, 42, 3845-3851.
20. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
21. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D. J.; Jessen, S.; Lu, V.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H. J.; Kroeger Koepke, M.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
22. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol 1995, 2, 407-15.
23. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
24. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
25. Richman, D. D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S. A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D.; Shih, C. K.; Mayers, M.; Griffin, J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68, 1660-1666.
26. Schinazi, R. F.; Larder, B. A.; Mellors, J. W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 1997, 5, 129-135.
27. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Emini, E. A. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
28. Balzarini, J.; Pelemans, H.; Aquaro, S.; Perno, C. F.; Witvrouw, M.; Schols, D.; De Clercq, E.; Karlsson, A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 1996, 50, 394-401.
29. Kleim, J. P.; Bender, R.; Billhardt, U. M.; Meichsner, C.; Riess, G.; Rosner, M.; Winkler, I.; Paessens, A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 1993, 37, 1659-1664.
30. Ranise, A.; Spallarossa, A.; Schenone, S.; Bruno, O.; Bondavalli, F.; Vargiu, L.; Marceddu, T.; Mura, M.; La Colla, P.; Pani, A. Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives. J. Med. Chem. 2003, 46, 768-781.
31. Cantrell, A. S.; Engelhardt, P.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kangasmetsa, J.; Kinnick, M. D.; Lind, P.; Morin, J. M., Jr.; Muesing, M. A.; Noreen, R.; Oberg, B.; Pranc, P.; Sahlberg, C.; Ternansky, R. J.; Vasileff, R. T.; Vrang, L.; West, S. J.; Zhang, H. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J. Med. Chem. 1996, 39, 4261-4274.
32. Bell, F. W.; Cantrell, A. S.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kinnick, M. D.; Lind, P.; Morin, J. M., Jr.; Noreen, R.; Oberg, B.; Palkowitz, J. A.; Parrish, C. A.; Franc, P.; Sahlberg, C.; Ternansky, R. J.; Vasileff, R. T.; Vrang, L.; West, S. J.; Zhang, H.; Zhou, X.-X. PETT compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem. 1995, 38, 4929-36.
33. Strickley, R. G.; Anderson, B. D. Solubilization and stabilization of an anti-HIV thiocarbamate, NSC 629243, for parenteral delivery, using extemporaneous emulsions. Pharm. Res. 1993, 10, 1076-1082 and references therein.
34. Wermuth, C. G. Strategies in the Search for New Lead Compounds or Original Work Hypotheses. In The Practice Of Medicinal Chemistry, 2nd ed.; Wermuth, C. G., Ed.; Academic Press: Boston, 2003; pp 76-77.
35. Campiani, G.; Morelli, E.; Fabbrini, M.; Nacci, V.; Greco, G.; Novellino, E.; Ramunno, A.; Maga, G.; Spadari, S.; Caliendo, G.; Bergamini, A.; Faggioli, E.; Uccella, I.; Bolacchi, F.; Marini, S.; Coletta, M.; Nacca, A.; Caccia, S. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity. J. Med. Chem. 1999, 42, 4462-70.
36. Vig, R.; Mao, C.; Venkatachalam, T. K.; Tuel-Ahlgren, L.; Sudbeck, E. A.; Uckun, F. M. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. Bioorg. Med. Chem. 1998, 6, 1789-97.
37. Sahlberg, C.; Noreen, R.; Engelhardt, P.; Hogberg, M.; Kangasmetsa, J.; Vrang, L.; Zhang, H. Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 1511-1516.
38. Mao, C.; Vig, R.; Venkatachalam, T. K.; Sudbeck, E. A.; Uckun, F. M. Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5- bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N′-[2-(5- bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 1998, 8, 2213-2218.
39. Uckun, F. M.; Mao, C.; Pendergrass, S.; Maher, D.; Zhu, D.; Tuel-Ahlgren, L.; Venkatachalam, T. K. N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5- bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′[2-(5- chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg. Med. Chem. Lett. 1999, 9, 2721-2726.
40. Hogberg, M.; Sahlberg, C.; Engelhardt, P.; Noreen, R.; Kangasmetsa, J.; Johansson, N. G.; Oberg, B.; Vrang, L.; Zhang, H.; Sahlberg, B. L.; Unge, T.; Lovgren, S.; Fridborg, K.; Backbro, K. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J. Med. Chem. 1999, 42, 4150-4160.
41. Mao, C.; Sudbeck, E. A.; Venkatachalam, T. K.; Uckun, F. M. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]- thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg. Med. Chem. Lett. 1999, 9, 1593-1598.
42. Uckun, F. M.; Pendergrass, S.; Maher, D.; Zhu, D.; Tuel-Ahlgren, L.; Mao, C.; Venkatachalam, T. K. N′-[2-(2-Thiophene)ethyl]-N′-[2-(5- bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg. Med. Chem. Lett. 1999, 9, 3411-3416.
43. Hogberg, M.; Engelhardt, P.; Vrang, L.; Zhang, H. Bioisosteric modification of PETT-HIV-1 RT-inhibitors: synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 2000, 10, 265-268.
44. Campiani, G.; Fabbrini, M.; Morelli, E.; Nacci, V.; Greco, G.; Novellino, E.; Maga, G.; Spadari, S.; Bergamini, A.; Faggioli, E.; Uccella, I.; Bolacchi, F.; Marini, S.; Coletta, M.; Fracasso, C.; Caccia, S. Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinyl-ethylpyridylthioureas as potent antiviral agents. Antiviral Chem. Chemother. 2000, 11, 141-155.
45. Dong, Y.; Venkatachalam, T. K.; Narla, R. K.; Trieu, V. N.; Sudbeck, E. A.; Uckun, F. M. Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg. Med. Chem. Lett. 2000, 10, 87-90.
46. Venkatachalam, T. K.; Sudbeck, E. A.; Mao, C.; Uckun, F. M. Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2000, 10, 2071-2074.
47. Mager, P. P. Evidence of a butterfly-like configuration of structurally diverse allosteric inhibitors of the HIV-1 reverse transcriptase. Drug Des. Discovery 1996, 14, 241-257.
48. Hsiou, Y.; Das, K.; Ding, J.; Clark, A. D. J.; Kleim, J. P.; Rosner, M.; Winkler, I.; Riess, G.; Hughes, S. H.; Arnold, E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 1998, 284, 313-323.
49. Mao, C.; Sudbeck, E. A.; Venkatachalam, T. K.; Uckun, F. M. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem. Pharmacol. 2000, 60, 1251-1265.
50. Das, K.; Clark, A. D. J.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; De Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
51. (a) Terret, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J. Combinatorial synthesis - The design of compound libraries and their application to drug discovery. Tetrahedron 1995, 51, 8135-8173.
52. (b) Kauffman, S.; Ellington, A. D. Thinking combinatorially. Curr. Opin. Chem. Biol. 1999, 3, 256-259.
53. Weller, H. N. Purification of combinatorial libraries. Mol. Diversity 1999, 4, 47-52.
54. An, H.; Cook, P. D. Methodologies for generating solution-phase combinatorial libraries. Chem. Rev. 2000, 100, 3311-3340.
55. Da Settimo, A.; Primofiore, G.; Ferrarini, P.; Livi, O.; Tellini, N.; Bianchini, P. Synthesis and local anesthetic activity of some N-β-diethylaminoethylphthalimides. Eur. J. Med. Chem. 1981, 16, 59-64 and references therein.
56. Drobnica, L.; Kristian, P.; Augustin, J. The Chemistry of the -NCS Group. In The Chemistry of Cyanates and Their Thio Derivatives; Patai, S., Ed.; John Wiley and Sons: New York, 1977; Part 2, p 1116 and references therein.
57. Walter, W.; Bode, K. D. Syntheses of thiocarbamates. Angew. Chem., Int. Ed. 1967, 6, 281-384.
58. Peck, R. M. Anomalous hydrolytic behavior of some basically-substituted phthalimides. A novel rearrangement of a 4-amino-quinoline side chain. J. Org. Chem. 1962, 27, 2677-2679.
59. Chamberlain, S. D.; Biron, K. K.; Dornsife, R. E.; Averett, D. R.; Beauchamp, L.; Koszalka, G. W. An enantiospecific synthesis of the human cytomegalovirus antiviral agent [(R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9- yl)methoxy)-4-hydroxybutyl]phosphonic acid. J. Med. Chem. 1994, 37, 1371-1377.
60. Tanaka, K.; Toda, F. Solvent-free organic synthesis. Chem. Rev. 2000, 100, 1025-1074.
61. Maass, G.; Immendoerfer, U.; Koenig, B.; Leser, U.; Mueller, B.; Goody, R.; Pfaff, E. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 2612-2617.
62. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
63. Kraulis, P. J. MolScript: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.
64. Esnouf, R. M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J Mol. Graphics Modell. 1997, 15, 132-134.